We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
-20.91%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$79.3M
AUM Growth
-$71.9M
Cap. Flow
-$39.4M
Cap. Flow %
-49.61%
Top 10 Hldgs %
66.81%
Holding
58
New
21
Increased
4
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$7.13M
2
TERN
Terns Pharmaceuticals
TERN
+$5.79M
3
ZLAB icon
Zai Lab
ZLAB
+$3.78M
4
ACLX
Arcellx
ACLX
+$3.21M
5
ARWR icon
Arrowhead Research
ARWR
+$2.73M

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$9.53M
2
SVRA icon
Savara
SVRA
+$8.3M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$5.78M
4
ROIV icon
Roivant Sciences
ROIV
+$5.6M
5
CYTK icon
Cytokinetics
CYTK
+$5.51M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.13B
$806K 1.02%
200,000
-1,865,144
-90% -$8.3M
BMEA icon
27
Biomea Fusion
BMEA
$92.5M
$752K 0.95%
+167,110
New +$1.7M
KURA icon
28
Kura Oncology
KURA
$964M
$746K 0.94%
+36,242
New +$745K
ZURA icon
29
Zura Bio
ZURA
$518M
$548K 0.69%
+156,626
New +$638K
ATYR
30
aTyr Pharma
ATYR
$50M
$488K 0.62%
+313,028
New +$545K
PEPG icon
31
PepGen
PEPG
$156M
$467K 0.59%
29,249
-85,136
-74% -$1.22M
KPTI icon
32
Karyopharm Therapeutics
KPTI
$216M
$464K 0.58%
+35,632
New +$590K
EYPT icon
33
EyePoint Inc
EYPT
$1.12B
$329K 0.42%
+37,838
New +$529K
MRNS
34
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$306K 0.39%
261,861
-303,689
-54% -$760K
MRSN
35
DELISTED
Mersana Therapeutics
MRSN
$221K 0.28%
+4,403
New +$318K
LSB
36
DELISTED
LakeShore Biopharma
LSB
$200K 0.25%
30,792
– –
CMPS
37
Compass Pathways
CMPS
$1.67B
$196K 0.25%
+32,497
New +$256K
SYRS
38
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$195K 0.25%
+37,789
New +$199K
SPRB
39
Spruce Biosciences
SPRB
$120M
$40.4K 0.05%
1,040
-4,830
-82% -$259K
ANNX icon
40
Annexon
ANNX
$950M
– –
-155,728
Closed -$1.12M
ASND icon
41
Ascendis Pharma A/S
ASND
$17.1B
– –
-12,754
Closed -$1.93M
AUPH icon
42
Aurinia Pharmaceuticals
AUPH
$2.05B
– –
-98,691
Closed -$494K
JBIO
43
Jade Biosciences
JBIO
$1.27B
– –
-3,150
Closed -$3.26M
AXSM icon
44
Axsome Therapeutics
AXSM
$11.8B
– –
-36,607
Closed -$2.92M
DAWN
45
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-349,679
Closed -$5.78M
DYN icon
46
Dyne Therapeutics
DYN
$3.92B
– –
-99,822
Closed -$2.83M
IDYA icon
47
IDEAYA Biosciences
IDYA
$3.47B
– –
-217,070
Closed -$9.53M
INZY
48
DELISTED
Inozyme Pharma
INZY
– –
-112,739
Closed -$864K
IONS icon
49
Ionis Pharmaceuticals
IONS
$8.99B
– –
-120,896
Closed -$5.24M
KALV
50
DELISTED
KalVista Pharmaceuticals
KALV
– –
-32,025
Closed -$380K
1
2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Superstring Capital Management held 58 positions worth $79.3M, down 48% from $151M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Superstring Capital Management withdrew a net $39.4M in Q2 2024, closing 19 positions and reducing 13 holdings. Its most notable exit was IDEAYA Biosciences, an estimated $9.53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Legend Biotech worth $6.85M.

  • Superstring Capital Management's largest Q2 2024 buy was Legend Biotech: 154,665 shares worth $6.85M.
  • Superstring Capital Management added most to Keros Therapeutics in Q2 2024, an estimated $2.17M increase.
  • Superstring Capital Management's biggest Q2 2024 reduction was Savara, cutting an estimated $8.3M.
  • Superstring Capital Management fully exited IDEAYA Biosciences in Q2 2024, selling an estimated $9.53M.
  • Superstring Capital Management's ten largest holdings make up 67% of its $79.3M portfolio in Q2 2024.
  • Superstring Capital Management opened 21 new positions and closed 19 in Q2 2024.
  • Superstring Capital Management's portfolio value fell 48% quarter-over-quarter to $79.3M.

Based on Superstring Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.